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16 Oral PresentationsCD141 cellswere also noted inbothCD341 andMNCrecipientmice
(p# 0.05, n5 3). No significant change in CD191 cells was noted in
any treatment group. This data suggests that UC-MSC have the abil-
ity to enhance short term myeloid reconstitution. It may therefore be
possible to develop UC-MSCmethodologies to both improve ex vivo
CB culture and increase transplant efficiency. Additionally, it may be
preferred that CB HSC and MSC be genetically identical or from an
HLA-matched or unmatched non-adult MSC tissue source.36
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Cord blood (CB) provides a readily available, ethnically-diverse
source of hematopoietic tissue for transplantation, however, low
cell dose delays engraftment and increases risk of graft failure. In ad-
dition, it has also been suggested that CB hematopoietic stem cells
(HSC) home less efficiently to the hematopoietic microenvironment
after transplantation when compared to bone marrow or peripheral
blood HSC. Homing mechanisms may rely, at least in part, on the
interaction between fucosylated glycoproteins on the surface of
HSC and P- and E-selectins expressed by the microvasculature of
the hematopoietic system. Glycoproteins expressed on the surface
of CB HSC appear to be poorly fucosylated. It has been proposed
that the use of a fucosyltransferase (FT) to increase levels of surface
glycoprotein fucosylation may improve homing to the bone marrow
and thereby improve engraftment. In an initial series of experiments,
levels of fucosylation of surface glycoproteins expressed on CB
CD341 cells were increased using FT-VI (Engraftin, America
Stem Cell). When subsequently injected into an NOD-SCID IL-
2Rgnull mouse model, the rate and magnitude of human engraftment
was greater than in mice receiving a similar dose of untreated CB
CD341 cells. Since CB recipients receive mononuclear cells
(MNC) rather than selected CD341 cells, the efficacy of a fucosyla-
tion strategy using CB MNC was investigated.
Methods: MNC were obtained from a frozen CB unit. Half was
untreated and half fucosylated: incubation for 30 minutes at room
temperature with 1 mM GDP b-Fucose, 1 mM MnCl2 and FT-
VI. Fucosylated and untreated MNC were washed and each trans-
planted into sublethally-irradiated (270 cGy) NOD-SCID
IL-2Rgnull mice (5 mice/gp). Mice each received 6  106 CB
MNC (containing 2.5 104 CD341 cells) by tail vein injection. En-
graftment was followed at weekly intervals by flow cytometric mea-
surement of human CD451 cells in the peripheral blood.
Results: 6 weeks after transplantation, recipients of fucosylated
MNC showed a maximal 14% human engraftment, as compared to
1% in recipients of untreated MNC.
Conclusion: Consistent with preliminary data following trans-
plantation of fucosylated, or untreatedCBCD341 cells, fucosylation
of CB MNC appears to improve both the rate and magnitude of en-
graftment. The efficacy of this technology will be explored in both
the single and double CB transplant settings and a clinical trial eval-
uating this approach will be designed and executed.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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PRE-ENGRAFTMENT SYNDROME (PES): A CLINICAL SYNDROME AFTER
CORD BLOOD (CB) TRANSPLANTATION NOT ASSOCIATED WITH ACUTE
GRAFT-VERSUS-HOST DISEASE (AGVHD) OR TRANSPLANT-RELATED
MORTALITY (TRM)
Patel, K.J., Rice, R.D., Hawke, R.M., Abboud, M., Heller, G.,
Scaradavou, A., Barker, J.N. Memorial Sloan-Kettering Cancer Center,
New York, NYPre-Engraftment Syndrome after cord blood transplantation
(CBT) is poorly characterized. Therefore, we conducted a review
of 52 double unit CBT recipients treated for high-risk hematological
malignancies to determine the incidence, manifestations, and
outcomes of PES. PES was defined as unexplained fever .38.3oC
(101oF) unresponsive to antibiotics and/or unexplained skin rash re-
sembling aGVHDoccurring prior to or at neutrophil recovery. CBT
recipients [median 38 years (range 3–66)] received either ablative (n
5 36) or non-myeloablative (NMA, n5 16) conditioning and CSA/
MMF. The cumulative incidence (CI) of sustained donor engraft-
mentwas 94% (95%CI:88–100)with neutrophil recovery at amedian
of 25 days in ablative and 11 days in NMA recipients. The CI of day
100 grade II-IV aGVHD and day 180 TRM were 40% (95%CI:
27–53) and 24% (95%CI:13–35), respectively. Sixteen (31%) pa-
tients fulfilled PES criteria: 15 with fever [median 39oC/102.2oF
(range 38.4–39.4oC) at onset] at a median of 9 days (range 5–12)
with 13 of these also having rash, and 1 having rash alone. The re-
maining 36 ‘‘no PES’’ patients included 5 without fever or rash, 26
with fever due to infection, and 5 with fever thought to be due to in-
fection and possible PES. Sixteen received IV methylprednisolone
(MP) treatment [14 PES, 2 with infection and possible PES; median
dose 1 mg/kg (range 0.5–2), median duration 3 days (range 2–44)].
Of 16 MP treated patients, 15 had fever resolution in #24 hours
and 1 in\48 hours. Two non-treated patients included 1 with spon-
taneous resolution of rash and 1 who remained febrile for 33 days.
While 3 patients had recurrent fever attributed to PES after MP ces-
sation this resolvedwith brief re-treatment. There was no association
between patient demographics, conditioning, or graft characteristics
and development of PES. There was also no association between
PES and neutrophil recovery, graft failure, aGVHD, or day 180
TRM.
Association between PES and Transplant Outcome
Median Grade 2-4
Total
(N 5 52)
Day Neutrophil
Recovery
Graft
FailureaGVHD
d 1 100 TRM d 1 100PES n516
(31%)Ablative
(n512):
23 days
(range 14-33);
NMA
(n54): 22 days
(range 7-36)n52 n55; 50 days
(range 34-70)n54No PES
n536
(69%)Ablative: 25 days
(range 13-43);
NMA: 11
days (range 7-22)n52 n514; 41 days
(range 29-99)n54p 5 0.75 p 5 0.67 p 5 0.79 p 5 0.22Eleven (69%) PES patients developed hypoxia6 pulmonary infil-
trates at a median of 12 days (range 7–15) as compared to 16 (44%)
non-PES patients (p 5 0.138). In summary, PES is common after
CBT, precedes neutrophil engraftment, is distinct from and does
not predict for aGVHD, and responds promptly to short course ste-
roids. Patients should not be diagnosed with early aGVHD or
treated with extended courses of steroids. Further investigation of
the etiology of PES and the toxicity (especially pulmonary
manifestations) is indicated.38
CORD BLOOD (CB) EXTENDS TRANSPLANT ACCESS TO RACIAL AND ETH-
NIC MINORITIES: A PROSPECTIVE STUDY OF 309 UNRELATED SEARCHES
IN PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES
Lee, S.S., Scaradavou, A., Hawke, R.M., Webb, K.A., Wells, D.S.,
Abboud, M., Papadopoulos, E.B., Kernan, N.A., Barker, J.N. Memorial
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HLA-A,B,C,DRB1 allelematch improves unrelated donor (URD)
hematopoietic stem cell (HSC) transplant outcome but limits the
number of suitable donors. In contrast, CB transplantation (CBT)
is associated with a reduced HLA-match requirement. Therefore,
we prospectively evaluated donor availability in 309 patients [median
Oral Presentations 1746 years (range 1–71)] between 10/05-5/08 with the hypothesis that
CB would extend transplant access. Adequate donor-recipient HLA-
match was $8/10 HLA-A,B,C,DRB1,DQ alleles for a T cell de-
pleted or $9/10 alleles for an unmodified URD graft. Adequate
CB units were $4/6 HLA-A,B antigen, DRB1 allele matched &
$1.5 107 TNC/kg/unit. Double unit grafts were used to augment
engraftment. URDs had priority; CB was chosen if no suitable URD
was available in the required time period. The 309 patients had
highly diverse ancestry with only 68 (22%) of northwest (NW) Eu-
ropean & 108 (35%) of non-European origin. The ancestry of 201
transplanted patients & the 15 not transplanted due to lack of suit-
able graft is shown below. The remaining 93 patients were not trans-
planted for other reasons. URD transplant recipients were
predominantly NW (32%), eastern (18%) or mixed (18%) European
with Asian, African & Hispanic patients combined accounting for
only 18%. In contrast, only 4 (8%) of CBT recipients were NW
European. While these patients received CB due to urgency (n 5
1), patient preference (n 5 1), or MD preference over mismatched
URD (n 5 2), the remaining 48 (92%) of CBT recipients including
15% Southern Europeans and 49% non-Europeans (13% Asian,
19% African, 15% Hispanic, 2% Middle Eastern) had no URD op-
tion. Of 15 patients not transplanted due to lack of any HSC source
10 were non-European including 6 of African ancestry. Their me-
dian weight [87kg (range 66–151)] was significantly higher than
CBT recipients [70kg (range 13–109); p\0.01] partially accounting
for their lack of suitable CB grafts. Thus, URD transplantation pre-
dominantly serves patients of NW, Eastern & mixed European an-
cestry with many Southern & non-Europeans having no suitable
URD. In contrast, CB significantly extends transplant access to all
but especially to both Southern & non-Europeans. Patients of
African ancestry are the most challenged to secure a suitable graft.
This data is compelling support for increased funding of public
CB banking & suggests that CB has the greatest potential to fulfill
the promise of being able to offer allograft to all regardless of race.
Patient Ancestry if Transplanted or No Graft
8-10/10 URD (n5149) 4-6/6 CB (n552) No graft (n515)NW Europe 47 (32%) 4 (8%) 1 (7%)
East Europe 27 (18%) 6 (12%) 0 (0%)
South Europe 15 (10%) 8 (15%) 3 (20%)
Mix: Europe 27 (18%) 8 (15%) 1 (7%)
Asian 6 (4%) 7 (13%) 0 (0%)
African 11 (7%) 10 (19%) 6 (40%)
Hispanic 10 (7%) 8 (15%) 3 (20%)
Middle East 5 (3%) 1 (2%) 0 (0%)
Mix: Non-Europe 1 (1%) 0 (0%) 1 (7%)*Significantly different (p#0.05).39
NEGATIVE IMPACT OF POST-THAW WASHING ON THE OVERALL SUR-
VIVAL (OS) AND DISEASE FREE SURVIVAL (DFS) OF PATIENTS RECEIVING
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Washing of CB after thawing prior to infusion into patients (pts)
is an accepted practice in CB transplantation. The potential clinical
benefits were extrapolated from early in vitro studies using units
processed by RBC reduction (RCR) with hetastarch. Other proce-
dures for processing (PD, RCR using gelatin or buffy coat) have
produced equally high quality CB with similar clinical outcome.
In this report, we analyzed the impact of post-thaw washing (W)
on clinical outcome using PD CB. A total of 487 PD CB was in-
fused into 434 pts with malignant or non-malignant diseases.
The decision to wash (222 pts) or not to wash (NW) CB after
thawing was at the discretion of individual transplant centers. Pt
matching was used to compare the W and NW cohorts. Pts wereassigned propensity scores based on age, weight, number of infused
CB, total nucleated cell (NC) dose, and HLA mismatches, then
each pt in the NW group was assigned a pt in the W group with
the nearest score to form a pair, allowing us to form a group of
129 W pts with the same diagnoses as those in a group of 129
NW pts. Outcome parameters including cumulative incidence
(CI) and days to ANC 500 and platelet 20k engraftment, grade
III-IV acute graft-versus-host-disease (aGvHD), extensive chronic
graft-versus-host-disease (cGVHD), 100-day and 1-year transplant
related mortality (TRM), 1-year relapse rate, OS and DFS, were
summarized in the table below. The analyses confirm that pts re-
ceiving NW CB have similar (aGvHD, relapse) or superior clinical
outcomes (ANC and platelet engraftment, cGVHD, TRM, OS and
DFS) to those receiving W units. It should be pointed out that
although the 100-day TRM appeared similar, the 1-year TRM
diverged significantly for the 2 groups. Pts receiving NW CB
had higher incidences of limited cGvHD but lower incidences of
extensive cGvHD as compared to those receiving W CB. Despite
this reduction in the severity and lower cumulative incidence of ex-
tensive cGvHD, pts receiving NW and W PD CB have similar re-
lapse rates, suggesting that Graft-versus-Leukemia effects may not
be compromised in the NW group. These observations also sug-
gest there may be a potential immunomodulatory mechanism
whereby the severity of cGvHD is reduced, which may contribute
to improved survival. In conclusion, our results suggest that post-
thaw washing of PD CB may be associated with poorer clinical out-
comes and prospective investigation on the effect of washing on
post CB transplant management may be warranted.
Impact of post-thaw washing of PD CB — All patients
Gr TRM*ANC
500* (d)Plt
20k* (d)III-IV
aGvHDExtensive
cGvHD*100
d/1 yr Relapse OS*/DFS*Washed 8564%
(27)6364%
(55)1563% 1663% 1863%/3464% 3165% 5464%/
4664%Unwashed 8665%
(20.5)7765%
(45)1763% 462% 1663%/2263% 2365% 6963%/
6264%Impact of post-thaw washing of PD CB — Matched PairsANC
500*
(d)Plt 20k*
(d)Gr III-IV
aGvHDExtensive
cGvHD*TRM* 100
d/1 yrRelapse OS*/
DFS*Washed 8366%
(28)5866%
(56.5)1463% 1764% 2164%/4165% 2866% 4865%/
4365%Unwashed 8966%
(21)7867%
(45)1464% 462% 1463%/2164% 2466% 6964%/
6165%40
CYTOTOXIC T LYMPHOCYTES (CTL) SPECIFIC FOR ADENOVIRUS AND
CMV CAN BE GENERATED FROM UMBILICAL CORD BLOOD FOR ADOP-
TIVE IMMUNOTHERAPY
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The naive phenotype of cord blood (CB) cells contributes to the
lower incidence and reduced severity of GvHD after umbilical cord
blood transplant (CBT). However, the relatively low cell numbers
and naivety of T-cell populations in CB grafts has lead to delayed im-
mune reconstitution and higher mortality due to infection. CMV and
adenovirus (Adv) are particularly problematic infections in patients af-
ter CBT. Previous studies have shown that adoptive immunotherapy
with peripheral blood-derived CTL directed against CMV and Adv
can effectively prevent the clinical manifestations of these viruses after
HSCT suggesting that a similar approach could be developed after
CBT. We hypothesized that CTL could be generated from CB for
clinical use to restore anti-viral immunity and reduce viral infection
post CBT. 40 106 CBmononuclear cells (available in the 20% frac-
tion of frozenCB units) were thawed and used for generation of bi-vi-
rus specific CTL. A clinical-grade recombinant Adv type 5 vector
pseudotyped with a type35 fiber carrying a transgene for CMVpp65
